SAME INSIGHTFUL CONTENT… NEW 3-DAY VIRTUAL FORMAT…
Note that the content of the Program Agenda below will remain, and be reformatted to accommodate our new 3-day virtual conference platform and schedule. Stay tuned for more details…
Key to this session will be addressing business needs across the lifecycle, whereby participants will:
• Develop an in-depth understanding of how a diverse range of facilitated activities (Rapid Immersion, Threat Assessment and Competitor Simulations) can help deliver strategic and competitive insights within an organization
• Appreciate the importance of leveraging the outcomes of workshops to inform and direct decision making
• Receive hands-on opportunities to apply learnings to a pharma case-study in a learning environment
Using business case studies, real-life experiences and validated theory, the INOVIS team will equip you with a number of go-to techniques that can be rapidly integrated into ongoing CI Practice, whether you’re a seasoned CI professional veteran, or newer to the field.
Many biopharma CI reports disseminated by the Agency are overly verbose, high-level and lack the substantive actionability required for internal usage – facilitating a seamless cascade to management & leadership.
Today’s workshop will translate classical stylistic business writing techniques including those of Strunk and White to the 21st-century biopharmaceutical CI and Strategy world.
In this workshop, we will facilitate two (2) breakouts during which “raw intelligence learnings” will be synthesized and translated into actionable CI deliverables using PowerPoint writing skills and infographic design techniques.
This Workshop is facilitated by David Alderman, President of Molekule Consulting, a global competitive intelligence and strategy consultancy dedicated to the life sciences and biopharmaceutical verticals. David has deep experience from early-development to late-lifecycle management and beyond within biopharma across the competitive landscape among myriad therapy areas, players and subject matters. David is a Subject Matter Expert on the biopharmaceutical vertical; with a particular focus on competition within branded biopharma, small molecule generics and biosimilars.
Topics we will cover:
• What must be in place to seamlessly transition you CI function from an environment of “business as usual” to “business as usual in an unusual environment”?
• What skills and tools need to be in place to adapt such a dramatic change of doing business?
• What processes work and what pitfalls to avoid?
The audience can expect to be able to participate actively in the “conversation” and contribute to the program
Still, others fail to realize that they must translate the importance of their insights into long-term gains for the stakeholders in the stakeholders’ perception.
One of pharma’s most successful CI professionals reveals 5 questions you must ask at the beginning of each project to ensure:
1. A dramatic return on investment for your CI efforts
2. Be recognized for the impact you are creating in your organization
3. Increase your resources and get your next promotion
In this presentation, Salvador Carlucci clearly demonstrates how CI professionals can educate their stakeholders on how to determine the real value of competitive intelligence and how to capture that value to propel their career. Filled with inspirational stories and practical advice, make sure not to miss this presentation.
• When and how should you adapt your CI plan to changing markets?
• What we can learn from tangible examples of primary CI’s impact on a business’s success?
For CI professionals, a machine learning-enabled research portal now can automatically mine and synthesize insights from all manner of documents — including industry news, scientific conference abstracts, primary and secondary market research, and even social media (screening out posts that may contain references to “adverse events”) — saving them valuable time, and zeroing in on the most relevant information needed to inform critical business decisions.
For social media planners, machine learning today can conduct a semantic analysis of keywords in social posts about a topic of interest, which yields clear guidance as to which terms have actual business relevance and are therefore worth investing in. (Consider that, on Twitter, the terms that most frequently co-occur with #cancer all have to do with astrology — #Scorpio, #Pisces, #Ascendant — which is not at all helpful to a pharmaceutical company marketing an anti-cancer drug.)
Attendees at this session will learn:
> the four essential ingredients needed to put machine learning to practical use in pharma CI
> best practices to ensure that your organization can safely use social media for research and marketing
> how one leading pharma company is employing machine learning in its CI efforts today
Technical Cost Modelling (TCM), a method developed at MIT in the 1980’s has long been the gold standard in benchmarking cost-of-goods sold which is time and resource intensive with a limited shelf-life. Although not as precise as TCM, Dig Worldwide’s bespoke COGIntel method allows rapid and cost effective COG benchmarking analysis that provides “good enough” competitive intelligence for strategic decision making. Performance gaps and areas of advantage or disadvantage become visible verses forgotten.
An illustrative CAR-T case study will form an integral part of the talk to help illustrate Dig Worldwide’s methodology.
Old-school and business-as-usual methodologies and deliverables will not cut it in an ever-changing business and technological environment that demands greater efficiencies in collection and analysis, and greater demands on ROI effectiveness of CI deliverables. As the American-Canadian writer William Gibson once said, “The future is already here – it’s just not very evenly distributed.” Prescient has surveyed CI stakeholders and has captured a list of the top challenges faced by CI teams. We will discuss the industry “norms” and the advent of budding new and futuristic solutions that will shake up the way we think of CI.
Acquisitions such as the CVS/Aetna merger and the Walgreens/Express Scripts group purchasing alliance are indications of new trends in the market. These trends have the potential to significantly change how decisions are made in the market. This session will present a set of future scenarios that depict the market based on extension of the trends. Using interactive tools, participants will model out strategies that pharmaceutical companies will need to implement to thrive in the environment.
1. New thinking about how the traditional pharmaceutical market will change by 2030
2. Expanded awareness of potential impacts from alliances between health insurance carriers, pharmacies, and pharmacy benefits managers
3. Exploration into ways the government can intervene in the market based on different scenarios
4. Broad strategic options for pharmaceutical companies
Early in life information on disease area and other new products as well as standard of care is crucial. As you enter into the 5 years preceding launch and Phase III needs become specific: registrational benchmarks, competition in terms of market share, trial and launch strategy.
Specifically this presentation will enable you to:
• Advance your understanding of core Gx/biosimilar market dynamics and corresponding CI solutions
• Set up a best-in-industry Gx/biosimilar regulatory intelligence (RI) and CI tracking program
• Understand Gx / biosimilar product development and entry strategies
• How has it changed care management? Some examples
• Who are the new/emerging voices that should be part of your new intelligence plan?
However, some basic truths still hold strong. This session will address Marjorie’s experience – the good, the bad and the ugly – in developing and maintaining a best-in-class CI program.
If you have an abundance of resources, is deep analytics the right answer? Ms. Saraos has led large CI programs at Roche/Genentech, consulted with various small non-commercialized biotechs, and is now at medium-sized biopharma, Jazz Pharmaceuticals. She will share her perspective on different ways to think about right sizing CI efforts that build trust and confidence with key stakeholders. Ms. Saraos will share types of bad behavior and lessons learned on how to get to a healthy CI place.
• Use of masks required: Please bring your own if preferred, but masks and hand sanitizer will also be provided.
• Greetings should be socially distanced: no handshakes, hugs, or kisses, etc.
• Meeting space will accommodate more spacing between attendees.
• The hotel experience will be entirely revamped with specific cleaning protocols.